CLSD beat EPS expectations by 21.14%
Nov 12, 2024, 11:32 PM
0.00%
What does CLSD do
Clearside Biomedical, headquartered in Alpharetta, Georgia, specializes in therapies delivered to the eye via the suprachoroidal space and has developed the approved product XIPERE. The company’s lead program, CLS-AX, is in Phase 2b clinical testing for wet AMD.
Clearside Biomedical (CLSD) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Clearside Biomedical's actual EPS was -$0.10, beating the estimate of -$0.13 per share, resulting in a 21.14% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.